Allozyne, the Seattle-based developer of modified protein drugs, said today it has obtained a license to “click chemistry” technology from the lab of Nobel Laureate K. Barry Sharpless at The Scripps Research Institute in San Diego. Allozyne’s lead drug candidate uses the chemical binding technique to attach a polymer to a genetically engineered protein for multiple sclerosis. Allozyne has the exclusive license to use the chemistry for certain therapeutic uses, and a non-exclusive license for diagnostic uses. Financial terms weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
